Clinicopathological features of hepatocellular carcinoma with fatty change: Tumors with macrovesicular steatosis have better prognosis and aberrant expression patterns of perilipin and adipophilin.
PAT family protein
adipophilin
fatty change
fatty liver
hepatocellular carcinoma
lipid droplet
macrovesicular steatosis
metabolic abnormality
microvesicular steatosis
perilipin
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
16
10
2019
accepted:
26
11
2019
pubmed:
14
1
2020
medline:
30
1
2021
entrez:
14
1
2020
Statut:
ppublish
Résumé
The clinicopathological characteristics of steatosis in hepatocellular carcinoma (HCC) remain unclear. Here, we elucidate the features of macrovesicular steatosis (MaS) and microvesicular steatosis (MiS) in HCC and their relationships with background liver steatosis. A total of 165 HCC lesions were classified as MaS-HCC, MiS-HCC, or conventional HCC (cHCC) according to the cutoff value of 30% MaS or MiS in tumor cells. We analyzed the clinicopathological differences among these groups. MaS-HCC had less portal vein invasion, a higher proportion of HCC with intratumoral fibrosis, and a lower cumulative risk of recurrence than MiS-HCC or cHCC. Moreover, both MaS-HCC and MiS-HCC had lower incidences of hepatitis virus infection and higher levels of HbA1c than cHCC. Background liver steatosis was also higher in MaS-HCC than in cHCC. Immunohistochemical expression of perilipin (Plin1) and adipophilin (ADRP), major proteins expressed on lipid droplet membranes, revealed that almost all lipid droplets in HCC were Plin1 negative, whereas those in background liver were positive. In contrast, ADRP was expressed on lipid droplets in both HCC and background liver. We concluded that MaS-HCC and MiS-HCC were associated with metabolic abnormalities but exhibited different biologic behaviors. Furthermore, lipid droplets in HCC were pathophysiologically different from those in background liver.
Substances chimiques
PLIN2 protein, human
0
Perilipin-1
0
Perilipin-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-209Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP19fk0210040
Informations de copyright
© 2020 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol 2019; 70: 531-44.
Fujimoto A, Furuta M, Shiraishi Y et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun 2015; 6: 6120.
Calderaro J, Couchy G, Imbeaud S et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017; 67: 727-38.
van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer 2011; 47: 1789-97.
Tsujikawa H, Masugi Y, Yamazaki K, Itano O, Kitagawa Y, Sakamoto M. Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness. Hum Pathol 2016; 50: 24-33.
Hatano M, Ojima H, Masugi Y et al. Steatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features. Hum Pathol 2019; 86: 222-32.
Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): A distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010; 34: 1630-36.
Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M. Hepatocellular carcinoma with steatohepatitic features: A clinicopathological study of Japanese patients. Histopathology 2014; 64: 951-62.
Salomaoa M, Remottia H, Vaughanb R, Siegelc A, Lefkowitcha J, Moreiraa R. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012; 43: 737-46.
Tandra S, Yeh MM, Brunt EM et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 2011; 55: 654-59.
Bove K, McAdams A, Partin J, Partin J, Hug G, Schubert W. The hepatic lesion in Reye's syndrome. Gastroenterology 1975; 69: 685-97.
Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 15539-48.
Kristiansen MNB, Veidal SS, Christoffersen C, Jelsing J, Rigbolt KTG. Molecular characterization of microvesicular and macrovesicular steatosis shows widespread differences in metabolic pathways. Lipids 2019; 54: 109-15.
Mashek DG, Khan SA, Sathyanarayan A, Ploeger JM, Franklin MP. Hepatic lipid droplet biology: Getting to the root of fatty liver. Hepatology 2015; 62: 964-67.
Zhang C, Liu P. The lipid droplet: A conserved cellular organelle. Protein Cell 2017; 8: 796-800.
Meyers A, Weiskittel TM, Dalhaimer P. Lipid droplets: Formation to breakdown. Lipids 2017; 52: 465-75.
Pawella LM, Hashani M, Eiteneuer E et al. Perilipin discerns chronic from acute hepatocellular steatosis. J Hepatol 2014; 60: 633-42.
Straub BK, Herpel E, Singer S et al. Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. Mod Pathol 2010; 23: 480-92.
Kaushik S, Cuervo AM. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat Cell Biol 2015; 17: 759-70.
Wallstab C, Eleftheriadou D, Schulz T et al. A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis. FEBS J 2017; 284: 3245-61.
Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, Londos C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J Biol Chem 1991; 266: 11341-46.
Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. J Lipid Res 1997; 38: 2249-63.
Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000; 33: 282-89.
Bidkhori G, Benfeitas R, Klevstig M et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc Natl Acad Sci USA 2018; 115: E11874-83.
Lin L, Ding Y, Wang Y et al. Functional lipidomics: Palmitic acid impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose metabolism. Hepatology 2017; 66: 432-48.
Yamashita T, Honda M, Takatori H et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 2009; 50: 100-110.
Friemel J, Rechsteiner M, Frick L et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res 2015; 21: 1951-61.
Zhai W, Lim TKH, Zhang T et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun 2017; 8: 4565.
Min JH, Kim YK, Lim S, Jeong WK, Choi D, Lee WJ. Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: Impact of intra-tumoral fat detected on chemical-shift images. Eur J Radiol 2015; 84: 1036-43.
Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: Prognostic features and survival. Gut 2001; 48: 103-109.
Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67.
Calvisi DF, Wang C, Ho C et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140: 1071-83.
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
Laurent C, Quaglia A, Foroni L, Bioulac-Sage P, Balabaud C, Dhillon AP. Genomic alteration is not associated with fatty and clear cell change in hepatocellular carcinomas and its precursor nodular lesions in cirrhotic liver. Hepatol Res 2006; 36: 40-47.
Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-67.
Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
Bickel PE, Tansey JT, Welte MA. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta 2009; 1791: 419-40.
Neis EP, Bloemen JG, Rensen SS et al. Effects of liver resection on hepatic short-chain fatty acid metabolism in humans. PLoS One 2016; 11: e0166161.
Valls C, Iannacconne R, Alba E et al. Fat in the liver: Diagnosis and characterization. Eur Radiol 2006; 16: 2292-308.